A5102789943- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Protease and Inhibitor Mechanisms
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cell Adhesion Molecules Research
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- Esophageal Cancer Research and Treatment
- Angiogenesis and VEGF in Cancer
- Retinoids in leukemia and cellular processes
- Nonmelanoma Skin Cancer Studies
- Economic and Financial Impacts of Cancer
- Effects of Radiation Exposure
- Peptidase Inhibition and Analysis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Statistical Methods in Clinical Trials
- Gastric Cancer Management and Outcomes
- PARP inhibition in cancer therapy
- Advanced Radiotherapy Techniques
- Plant Parasitism and Resistance
- Plant tissue culture and regeneration
- S100 Proteins and Annexins
Technical University of Munich
2006-2023
Spital Zollikerberg
2023
Klinikum rechts der Isar
2006-2018
Martin Luther University Halle-Wittenberg
2009-2012
Johannes Gutenberg University Mainz
2009-2012
Klinikum Fürth
2012
Ludwig-Maximilians-Universität München
2012
Deggendorf Institute of Technology
2009
Radboud University Nijmegen
2006-2009
German Breast group
2007-2009
This study was performed to evaluate skin toxicity during modern three-dimensional conformal radiotherapy (3D-CRT) and the importance of dose distribution patient related factors.This comprises 255 patients with breast cancer treated tangential after conserving surgery between 03/2012 05/2017. The median prescribed 50.4 Gy (range 50-50.4) 92.2% received a sequential boost 10-16 Gy. Adverse toxicities (according CTCAE v. 4.03 occurrence moist desquamations) were assessed at end treatment. in...
Today, more than 70% of patients with primary node-negative breast cancer are cured by local therapy alone. Many receive overtreatment adjuvant chemotherapy due to inadequate risk assessment. So far, few clinical trials have prospectively evaluated tumor biology based prognostic factors. Risk assessment a biological algorithm including invasion factors urokinase-type plasminogen activator (uPA) and its inhibitor type 1 (PAI-1) will assess up 35-55% as low-risk thus avoid chemotherapy. In...
Urokinase-type plasminogen activator (uPA) and its inhibitor inhibitor-1 (PAI-1) are key factors in tumour invasion metastasis. Increased levels of uPA and/or PAI-1 primary tissues correlate with aggressiveness poor patient outcome [1, 2]. In breast cancer, Duffy et al. [3] 1988 were the first to show that high enzymatic activity cancer was correlated advanced stage clinical outcome. 1989, Janicke [4] demonstrated antigen tissue measured by enzyme-linked immunosorbent assay (ELISA) also...
544 Background: ASCO Tumor Marker Guidelines 2007 recommended clinical routine use of the invasion markers uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 for risk assessment in N0 breast cancer pts (Harris et al, J Clin Oncol. 2007;25:5287). Ten-year follow-up data confirmatory prospective uPA/PAI-1 trial (CHEMO-N0) will be presented at 2009 Meeting (Harbeck al.). We conducted a further (NNBC 3-Europe) addressing direct comparison between risk-assessment by (UP)...
Abstract #1092 The American Society of Clinical Oncology 2007 Update Recommendations for the Use Tumor Markers in Breast Cancer suggests use invasion markers urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 risk assessment (Harris et al. JCO 25:5287). In 2003, we launched NNBC 3-Europe trial node negative breast cancer patients with following questions:
 1) Comparison risk-assessment: uPA/PAI-1 vs. clinico-pathological factors.
 2) adjuvant...
Nach der Risikoabschätzung entsprechend den Empfehlungen von St. Gallen 2007 werden mehr als 70 % Patientinnen mit nodalnegativem Mammakarzinom anhand klinisch-pathologischer Prognosefaktoren Gruppe mittlerem Rezidivrisiko zugeordnet. besteht hier bei hormonrezeptorpositiven Karzinomen eine Therapieoption oder ohne adjuvante Chemotherapie, und es gilt, diejenigen zu identifizieren, denen aufgrund ihres niedrigen Risikos Chemotherapie erspart kann. Zur Identifizierung dieser eignet sich das...
Abstract Background: Risk assessment in node-negative (N0) breast cancer patients (pts) is routinely performed by established clinico-pathological algorithms (CP) (Schmidt et al. Ann Oncol 2009). ASCO guidelines also recommend invasion markers uPA/PAI-1 (UP; Harris JCO 2007). The prospective randomized multicenter NNBC 3-Europe trial had two questions: 1) Does UP compared to the CP algorithm improve identification of low-risk patients? 2) addition taxanes adjuvant chemotherapy DFS...
10503 Background: Feasibility of risk assessment in node negative breast cancer using the invasion markers urokinase-type plasminogen activator uPA and its inhibitor PAI-1 has been demonstrated several prospective retrospective studies a large meta analysis. Patients with low and/or concentrations tumor tissue levels have an excellent 5-year overall survival (>95%) even without any adjuvant therapy. Use these molecular may spare chemotherapy approximately one half node-negative patients....
e11512 Background: Docetaxel is the most effective mono-substance in metastatic BC and highly adjuvant chemotherapy. Early docetaxel-monotherapy data primary systemic therapy (PST) showed a pCR of 18% (Amat et al; 2003), comparable with pCR-rates standard PST combination HEDON was conducted to evaluate efficacy docetaxel ± T regard (defined as absence invasive non-invasive breast lymph nodes) endpoint; secondary endpoints were safety, conservation rate 5-yr DFS. Additionally Trans-HEDON...
11081 Risk-assessment in N0 breast cancer is still controversial. In line with St. Gallen, only few patients (pts) are considered at such low risk of relapse, that adjuvant chemotherapy could be avoided. Various groups have started clinical trials aimed improved risk-assessment by gene or protein analysis the primary tumor. We launched NNBC 3-Europe trial asking following questions: Is identification low- pts invasion markers uPA and PAI-1 more effective than Gallen criteria? using an...
In node-negative breast cancer (NNBC), a high risk of recurrence is determined by clinico-pathological or tumor-biological assessment. Taxanes may improve adjuvant chemotherapy.NNBC 3-Europe, the first randomized phase-3 trial in (BC) with assessment, recruited 4146 patients from 2002 to 2009 153 centers. Risk assessment was performed factors (43%) biomarkers (uPA/PAI-1, urokinase-type plasminogen activator/its inhibitor PAI-1). High-risk received six courses 5-fluorouracil (500 mg/m2),...
Das genomische Grading des Oncotype DX Tests legt einen individuellen Risikoscore (RS) als Entscheidungsdeterminante für die adjuvante Therapie rezeptorpositven Mammakarzinoms fest. Auf der Basis retrospektiver Analysen wird unabhängig vom Nodalstatus ab einem RS>25 von Benefit adjuvanten Chemotherapie ausgegangen. Ca. 30% getesteten Patientinnen erfahren Wechsel Therapieentscheidung. Zunehmend außerhalb klinischer Protokolle über Testdurchführung aufgeklärt; eine gesicherte Kostenübernahme...
Goals: Not all breast cancer patients with metastatic sentinel lymph node (SLN) have additional metastasis in non-SLN.Many prediction models had been developed for saving of axillary dissection (ALND).The goals this study are to identify predictive factors non-SLN and develop simplest model.Methods: We analyzed 130 as training dataset.The independent validation dataset consisted 82 other institute.Various were through logistic regression model machine learning tools: artificial neural...
Abstract Background:ASCO Tumor Marker Guidelines 2007 recommended clinical routine use of the invasion markers uPA and PAI-1 for risk assessment in N0 breast cancer patients (Harris et al. JCO 2007; 25:5287). We conducted prospective NNBC 3-Europe trial addressing direct comparison between risk-assessment by uPA/PAI-1 clinico-pathological factors, optimization adjuvant chemotherapy high-risk pts: FEC*3-Doc*3 vs. standard FE100C*6.Study Design:Risk was based on grade, G2 tumors either status...
Problemstellung: Leitlinienempfehlungen haben die SLNB in klinische Routine weitgehend implementiert.